Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
暂无分享,去创建一个
A. Rossi | M. Di Nicola | A. Gallamini | D. Caracciolo | F. Ciceri | A. Rambaldi | R. Passera | P. Corradini | A. Gianni | A. Barbui | S. Cortelazzo | M. Magni | C. Patti | A. Gueli | C. Tarella | A. Carobbio | G. Parvis | F. Benedetti | V. Zoli | M. Bosa | M. Sorio | A. Mulé | A. Mulè